Literature DB >> 21389043

The risk of myocardial infarction in rheumatoid arthritis and diabetes mellitus: a Danish nationwide cohort study.

Jesper Lindhardsen1, Ole Ahlehoff, Gunnar Hilmar Gislason, Ole Rintek Madsen, Jonas Bjerring Olesen, Christian Torp-Pedersen, Peter Riis Hansen.   

Abstract

OBJECTIVES: To examine in a nationwide cohort whether the risk of myocardial infarction (MI) in patients with rheumatoid arthritis (RA) is comparable to the risk in patients with diabetes mellitus (DM).
METHODS: The study included the entire Danish population followed from 1 January 1997 until 31 December 2006. Through individual level-linkage of nationwide administrative registers, the authors identified subjects who developed RA and DM. The risk of MI was analysed using multivariable Poisson regression models including data on cardioprotective drugs, comorbidity and socioeconomic status.
RESULTS: From a total of 4,311,022 individuals included in the cohort, 10,477 and 130,215 individuals developed RA and DM respectively. The overall incidence rate ratio (IRR) of MI in RA was 1.7 (95% CI 1.5 to 1.9), which was similar to the risk in DM (1.7 (1.6 to 1.8); p=0.64 for difference). The risk was significantly increased in all groups when stratifying on age and gender, with higher RRs in younger patients. This was especially pronounced in women <50 years with RA or DM, who were subject to a sixfold increase in RR. The RA-related risk of MI was unaffected by the duration of pharmacological RA treatment and corresponded to the overall risk of MI observed in non-RA subjects, who were on the average 10 years older.
CONCLUSIONS: RA is associated with the same risk of MI as DM, and the risk of MI in RA patients generally corresponded to the risk in non-RA subjects 10 years older.

Entities:  

Mesh:

Year:  2011        PMID: 21389043     DOI: 10.1136/ard.2010.143396

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  122 in total

Review 1.  Perioperative care for patients with rheumatic diseases.

Authors:  Bharath M Akkara Veetil; Tim Bongartz
Journal:  Nat Rev Rheumatol       Date:  2011-11-15       Impact factor: 20.543

Review 2.  My treatment approach to rheumatoid arthritis.

Authors:  John M Davis; Eric L Matteson
Journal:  Mayo Clin Proc       Date:  2012-07       Impact factor: 7.616

3.  Management of cardiovascular risk in patients with rheumatoid arthritis: evidence and expert opinion.

Authors:  Inge A M van den Oever; Alper M van Sijl; Michael T Nurmohamed
Journal:  Ther Adv Musculoskelet Dis       Date:  2013-08       Impact factor: 5.346

4.  Safety and Impact of Low-dose Methotrexate on Endothelial Function and Inflammation in Individuals With Treated Human Immunodeficiency Virus: AIDS Clinical Trials Group Study A5314.

Authors:  Priscilla Y Hsue; Heather J Ribaudo; Steven G Deeks; Tanvir Bell; Paul M Ridker; Carl Fichtenbaum; Eric S Daar; Diane Havlir; Eunice Yeh; Ahmed Tawakol; Michael Lederman; Judith S Currier; James H Stein
Journal:  Clin Infect Dis       Date:  2019-05-17       Impact factor: 9.079

Review 5.  Abatacept for Treatment of Rheumatoid Arthritis: Special Focus on the Elderly.

Authors:  Martin Soubrier; Clement Lahaye; Zuzana Tatar
Journal:  Drugs Aging       Date:  2018-05       Impact factor: 3.923

6.  Primary care providers' awareness, knowledge, and practice with regard to cardiovascular risk in patients with rheumatoid arthritis : PCPs' awareness, knowledge, and practice with regard to CV risks in patients with RA.

Authors:  Stella Pak
Journal:  Clin Rheumatol       Date:  2019-12-24       Impact factor: 2.980

Review 7.  Cardiovascular Safety of Biologics and JAK Inhibitors in Patients with Rheumatoid Arthritis.

Authors:  Eun Ha Kang; Katherine P Liao; Seoyoung C Kim
Journal:  Curr Rheumatol Rep       Date:  2018-05-30       Impact factor: 4.592

Review 8.  Atherosclerotic cardiovascular disease prevention in rheumatoid arthritis.

Authors:  Anne Grete Semb; Eirik Ikdahl; Grunde Wibetoe; Cynthia Crowson; Silvia Rollefstad
Journal:  Nat Rev Rheumatol       Date:  2020-06-03       Impact factor: 20.543

Review 9.  Co-morbidity index in rheumatoid arthritis: time to think.

Authors:  Yasser El Miedany
Journal:  Clin Rheumatol       Date:  2015-10-26       Impact factor: 2.980

Review 10.  Cardiovascular comorbidity in rheumatic diseases.

Authors:  Michael T Nurmohamed; Maaike Heslinga; George D Kitas
Journal:  Nat Rev Rheumatol       Date:  2015-08-18       Impact factor: 20.543

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.